BOEHRINGER INGELHEIM INTERNATIONAL GMBH

History

Year	Detail
1885-1948	Innovative beginnings
1885	Albert Boehringer purchased a small tartar factory in Nieder-Ingelheim, now part of Ingelheim am Rhein.
1893	Experiments were undertaken to produce citric acid, which resulted in the formation of lactic acid. After two years, the company registered its first patent for a new process for manufacturing lactic acid baking powder.
1917	The research department was established on the initiative of the chemist Heinrich Wieland, a cousin of Albert Boehringer. This R&D department will be responsible for all research and development activities across the company’s acid, alkaloid, and pharmaceutical sectors.
1933-1945	The National Socialism period also affected Boehringer Ingelheim as a manufacturing company. Some of its seizure of power included delayed production of consumer goods, import limitations, and foreign currency restrictions.
1945	The CELA Landwirtschaftliche Chemikalien GmbH (Agricultural Chemicals Ltd.) was founded to manufacture pesticides that help farmers safeguard their crops against the potato beetle plague

1948-1990	Going global
1948	The first foreign subsidiary, Bender & Co. GmbH, was established three years after the end of the Second World War.
1950	Boehringer Ingelheim collaborated with Pfizer & Co., the American pharmaceutical company in the field of antibiotics.
1955	Boehringer Ingelheim received an offer from Pfizer & Co. to sell and distribute Terramycin antibiotics. This development marks the beginning of the animal health sector in Boehringer Ingelheim.
1961	The Institute for Pharmaceutical Research, focused on virology and pharmacology, was founded in Vienna.
1977	The Boehringer Ingelheim Foundation was established to promote biology, chemistry, medicine, and pharmaceutical science research.
1989	The company launched Alveofact, a surfactant substitute for respiratory distress syndrome in newborns.

1990-2024	Value through Innovation
1993	The German pharmaceutical business with two sites in Ingelheim and Biberach was under one joint management.
2000	Boehringer Ingelheim Center sets new standards in Ingelheim, which include administrative and corporate functions at the heart of company operations.
2003	Boehringer Ingelheim invested approximately $288.4 million to expand its biopharmaceutical active ingredient production facilities in Biberach.
2004	Boehringer Ingelheim acquired STEAG Microparts GmbH, a micro-technology company in Germany, from STEAG AG Essen.
2011	Boehringer Ingelheim and Eli Lilly received authorization from the European Commission to market Trajenta (linagliptin), a drug used to treat adults with type 2 diabetes.
2019	Boehringer Ingelheim partnered with Lupin Ltd. to develop and commercialize a novel Oncology drug to treat KRAS-driven cancers. Under this agreement, the company will strengthen its portfolio for patients with lung and gastrointestinal cancers.
2023	Boehringer Ingelheim signed an agreement with IBM to utilize its foundation model technologies to discover novel candidate antibodies for developing efficient therapeutics.
2023	Boehringer Ingelheim unveiled its advanced Biologicals Development Center (BDC) in Biberach an der Riß, Germany. With an investment of 378.6 million, the company significantly enhances its innovation power and development of biopharmaceutical development capabilities in Germany.
2024	Boehringer Ingelheim opened its new biogas power plant in Ingelheim site, Germany. The new biomass power plant minimizes the CO2 emissions produced by the energy generated at the plant by 50%.